

### Correction to *Lancet Oncol* 2019; 20: 1148–59

Bonvalot S, Rutkowski PL, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (*Act.In.Sarc*): a multicentre, phase 2–3, randomised, controlled trial. *Lancet Oncol* 2019; **20**: 1148–59—In this Article, the funder PharmaEngine, Inc, was inadvertently omitted and has now been added to the Funding line in the Summary and to the Acknowledgments. A repeated sentence has been deleted from the fifth paragraph of the Statistical Analysis section of the Methods, and some minor typographical errors have been corrected throughout the paper. These corrections have been made to the online version as of Sept 2, 2019.

### Correction to *Lancet Oncol* 2019; 20: 1171–82

Nené NR, Reisel D, Leimbach A, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. *Lancet Oncol* 2019; **20**: 1171–82—In figure 2A of this Article, the odds ratio for “Non-white ethnicity” has been corrected to 1.65. Figure 2D has been updated so that the odds ratios presented are correctly aligned with the relevant subgroup. Finally, some small changes have been made to supplementary table 17 on p 17 of the appendix. These changes have been made to the online version of the Article as of Sept 2, 2019.

### Correction to *Lancet Oncol* 2019; 20: 1211–25

GBD 2017 Childhood Cancer Collaborators. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. *Lancet Oncol* 2019; **20**: 1211–25—In figure 4 of this Article, the order of countries should be by absolute disability-adjusted life-years. The following sentence has been added to the figure 4 caption: “SDI quintiles are ordered from high to low SDI quintile, and GBD super-regions are alphabetically ordered.” The next sentence should read: “Country order selected by total absolute DALYs; countries with the greatest total absolute DALYs, of the fifty most populous countries in the world, are listed first.” Amendments have been made to the affiliations list at the end of the Article. This correction has been made to the online version as of Aug 6, 2019.

### Correction to *Lancet Oncol* 2019; 20: 1273–85

de Boer SM, Powell ME, Mileskin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncol* 2019; **20**: 1273–85—In this Article, data (hazard ratios, 95% CIs, and p values) in the following sentence on p 1279 have been corrected: “In women with stage I–II disease, 5-year overall survival was 83.8% (95% CI 78.4–89.5) with chemoradiotherapy versus 82.0% (95% CI 76.5–87.7) with radiotherapy alone (HR 0.84 [95% CI 0.52–1.38]; p=0.50), and 5-year failure-free survival was 81.3% (95% CI 74.7–86.3) with

chemoradiotherapy versus 77.3% (95% CI 70.5–82.7) with radiotherapy alone (HR 0.87 [95% CI 0.56–1.36] p=0.54; appendix p 8).” On p 1282, the same data (hazard ratios and 95% CIs) in the following sentence have also been corrected: “For women with stage I–II endometrial cancer, combined adjuvant treatment yielded only a small absolute improvement of 2% (HR 0.84; 95% CI 0.52–1.38) in 5-year overall survival and of 4% (0.87; 0.56–1.36) in failure-free survival.” These corrections have been made to the online version as of Sept 2, 2019, and the printed version is correct.

### Correction to *Lancet Oncol* 2019; 20: e417–33

Herrera FG, Irving M, Kandalaft LE, Coukos G. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. *Lancet Oncol* 2019; **20**: e417–33—Figure 1 in this Series paper has been updated. This correction has been made as of July 30, 2019.

### Correction to *Lancet Oncol* 2019; 20: e503–21

Spence D, Dyer R, Andall-Breton G, et al. Cancer control in the Caribbean island countries and territories: some progress but the journey continues. *Lancet Oncol* 2019; **20**: e503–21—The affiliations of authors Dingle Spence and M Austin Argentieri have been corrected in the online version as of Sept 2, 2019.

Published Online  
August 6, 2019  
[http://dx.doi.org/10.1016/S1470-2045\(19\)30530-3](http://dx.doi.org/10.1016/S1470-2045(19)30530-3)

Published Online  
July 30, 2019  
[http://dx.doi.org/10.1016/S1470-2045\(19\)30521-2](http://dx.doi.org/10.1016/S1470-2045(19)30521-2)